ICEECE2012 Poster Presentations Cardiovascular Endocrinology and Lipid Metabolism (74 abstracts)
Cardiovascular function and IGF1 deficit (IGF1-D) in β-thalassemia major
V. Atzori 1 , F. Pigliaru 1 , S. Vacquer 2 , M. Carta 2 , A. Spiga 2 , P. Bina 3 , M. Pili 3 , M. Manca 3 , M. Lai 2 & S. Mariotti 1
1University of Cagliari, Monserrato - Cagliari, Italy; 2University of Cagliari, Cagliari, Italy; 3Microcitemico Hospital, Cagliari, Italy.
Introduction: Both GH and IGF1 have important effects on the heart mass and contractility and deficiency of either hormone is associated with increased cardiovascular morbidity and mortality. GH/IGF1 axis abnormalities (mostly primary or secondary IGF1-D) are frequent in adult patients with β-thalassemia major (β-Thal). IGF1-D could therefore contribute with iron overload to the heart’s damage of β-Thal patients, but this question has been little investigated so far.
Purpose: Retrospective evalutation of cardiovascular function by echocardiographic parameters in a cohort of 80 patients with β-Thal, 55 F and 25 M, aged 31–52 years, subdivided according to blood levels IGF1 using a cutoff of 70 ng/ml, indicative of marked IGF1-D for the entire age range.
Results: Patients with IGF1 <70 ng/ml showed significantly larger left atrium (LA), left ventricle (LV) and, to a lesser extent, right ventricle (RV) diameters (Table). No significant difference was found between the two groups in aorta diameter, ejection fraction (EF) and ferritin levels. The cumulative prevalence of several cardiac complications (atrial fibrillation, atrioventricular block, right or left bundle branch block, heart failure and cor pulmonale) was significantly (P<0.01) higher (25 in 53 patients) in patients with IGF1 <70 ng/ml, when compared to those with IGF1 >70 ng/ml (4 in 28 patients).
Conclusions: Our data provide evidence for a negative effect of IGF1-D on heart of β-Thal patients. These data provide the basis for further studies and suggest a potential indication for treatment with rhGH and/or IGF1 in β-Thal patients with low serum IGF1.
| Patients (n=80) | Ferritin (ng/ml: m±S.D.) | EF (%: m±S.D.) | LA (mm: m±S.D.) | LV (mm: m±S.D.) | RV (mm: m±S.D.) | AORTA (mm: m±S.D.) |
| IGF1 <70 ng/ml (n=53) | 1004.1±784.4 | 64.3±6.7 | 38.1±5.1 | 49.0±5.2 | 19.8±7.0 | 30.0±4.1 |
| IGF1 >70 ng/ml (n=27) | 769.7±521.8 | 66.4±5.0 | 33.9±5.3 | 46.1±5.0 | 16.6±6.3 | 28.8±3.0 |
| P | 0.15 | 0.15 | 0.0004 | 0.014 | 0.032 | 0.18 |
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more